Neurology

The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?

FDA Approves Riluzole Oral Film for Treatment of Amyotrophic Lateral Sclerosis

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

Midazolam Nasal Spray Treatment for Seizure Clusters to be Available in December

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

Risdiplam Granted Priority Review for Spinal Muscular Atrophy

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Top news of the day from across the health care landscape.

FDA Approves Biosimilar for Multiple Inflammatory Conditions

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

Cenobamate Leads to Significant Reductions in Adult Patients with Partial-Onset Seizures

Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.

Study: Stem Cell Transplant Reverses Neuromyelitis Optica

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

Progenitor Cells Found to Play Large Role in Multiple Sclerosis

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

New Study Identifies Potential Genetic Markers for Severe MS Symptoms

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

FDA Approves Diroximel Fumarate for Relapsing Forms of Multiple Sclerosis

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

FDA Approves Therapy for Children with Lower Limb Spasticity

Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX^®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.

New Treatment Available for “Off” Episodes in Patients with Parkinson Disease

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

The Pharmacy Times® Neurology resource center provides a home for all of the latest clinical information that both neurologists and pharmacists that work within the field could find valuable. With articles covering updates from the robust pipeline of novel neurological therapies, and the newest data from all phases of clinical trials and studies in the space, it also serves as a hub of coverage from ongoing conferences and annual meetings of neurological associations.